Home › Waldenstrom Macroglobulinemia
Waldenstrom Macroglobulinemia clinical trials recruiting in the U.S.
30 studies for Waldenstrom Macroglobulinemia are recruiting participants at sites across the United States.
Cities with the most studies
- Durham, NC10 studies
- Boston, MA9 studies
- Denver, CO7 studies
- Dallas, TX6 studies
- New York City, NY6 studies
- Edison, NJ6 studies
- Houston, TX6 studies
- Columbus, OH5 studies
- Seattle, WA5 studies
- Milwaukee, WI5 studies
- Rochester, MN5 studies
- Queens, NY4 studies
- Chicago, IL4 studies
- Washington, DC4 studies
- Baldwin Park, CA4 studies
- Cincinnati, OH3 studies
- Salt Lake City, UT3 studies
- Portland, OR3 studies
- Nashville, TN3 studies
- Jacksonville, FL3 studies
- Richmond, VA3 studies
- Miami, FL3 studies
- Cleveland, OH3 studies
- Philadelphia, PA3 studies
By state
- Arizona4 studies
- California12 studies
- Colorado8 studies
- Florida7 studies
- Georgia3 studies
- Illinois5 studies
- Iowa3 studies
- Maryland5 studies
- Massachusetts11 studies
- Michigan5 studies
- Minnesota5 studies
- New Jersey7 studies
- New York8 studies
- North Carolina12 studies
- Ohio9 studies
- Oregon4 studies
- Pennsylvania3 studies
- Tennessee3 studies
- Texas11 studies
- Utah3 studies
- Virginia3 studies
- Washington7 studies
- Wisconsin6 studies
Recently updated studies
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
RecruitingObservational study
Ages 18 to 110 · All sexes · Updated Sep 28, 2026 · NCT00923507Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04840602Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT04728893A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07101328Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 1, 2026 · NCT06561347A Study of ARC-02 in B-cell NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07691606AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT06340737Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT07426484Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 7, 2026 · NCT05640102A Long-term Extension Study of PCI-32765 (Ibrutinib)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT01804686A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06708897A Study of APG-3288 in Relapsed/Refractory Blood Cancers
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 30, 2026 · NCT07424833A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT05131022Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Recruiting
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06860880Registry of Older Patients With Cancer
RecruitingObservational study
Ages 65 and older · All sexes · Updated Jun 29, 2026 · NCT01137825A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 17, 2026 · NCT07231952Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
RecruitingObservational study
Ages 18 and older · All sexes · Updated May 7, 2026 · NCT02269592SynKIR-310 for Relapsed/Refractory B-NHL
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 14, 2026 · NCT06544265A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 20, 2026 · NCT04830137Epcoritamab in Previously Treated WM
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT06510491Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
RecruitingObservational study
All ages · All sexes · Updated Feb 27, 2026 · NCT06151730Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT04775745Study of SGR-1505 in Mature B-Cell Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT05544019AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 10, 2025 · NCT05602363From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.